✦ LIBER ✦

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

✍ Scribed by Roy S Herbst; Rafat Ansari; Frederique Bustin; Patrick Flynn; Lowell Hart; Gregory A Otterson; Gordana Vlahovic; Chang-Heok Soh; Paula O'Connor; John Hainsworth

Book ID: 117308420
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 338 KB
Volume: 377
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(11)60545-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line erlotinib in patients with ad

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

✍ Siow Ming Lee; Iftekhar Khan; Sunil Upadhyay; Conrad Lewanski; Stephen Falk; Ger 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 314 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer

✍ Spigel, D. R.; Burris, H. A.; Greco, F. A.; Shipley, D. L.; Friedman, E. K.; Wat 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 161 KB

A phase II study of erlotinib in combina

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

✍ Ciuleanu, T.; Tsai, C.-M.; Tsao, C.-J.; Milanowski, J.; Amoroso, D.; Heo, D.S.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 718 KB

Rationale and Design of MARQUEE: A Phase

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

✍ Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Se 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 332 KB

Afatinib versus placebo for patients wit

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

✍ Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; San 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 373 KB

Randomized open-label non-comparative mu

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

✍ Auliac, J.B.; Chouaid, C.; Greiller, L.; Monnet, I.; Le Caer, H.; Falchero, L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 484 KB